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Mesenchymal stromal cells derived from amnion (AM-MSCs) can be easily obtained in large quantity by
less invasive method in comparison to bone marrow-derived MSCs (BM-MSCs). However, the biological
and immunosuppressive properties of AM-MSCs are still poorly characterized. Previous studies de-
monstrated that BM-MSCs expressed indoleamine 2,3-dioxygenase (IDO) to suppress T-cell responses.
This study was designed to address whether IDO contributes to the immunosuppressive function of AM-
MSCs. MSCs isolated from amnion were cultured in complete medium similar to BM-MSCs. After culture,
AM-MSCs exhibited spindle shape morphology and expressed MSC markers similar to that of BM-MSCs.
In addition, AM-MSCs were able to differentiate into adipocytes and osteoblasts. Fascinatingly, AM-MSCs
and BM-MSCs exhibited comparable degree of immunosuppressive effect when they were co-cultured
with activated T-cells. In addition, IDO secreted by AM-MSCs was responsible for induction of im-
munosuppressive activities in the same manner as BM-MSCs. Taken together; the results of the present
study demonstrate that while AM-MSCs and BM-MSCs show similar immunosuppressive effect, AM-
MSCs may have additional advantage over the BM-MSCs in terms of availability. Therefore, AM-MSCs
might be considered a potential source for therapeutic applications especially for treatment of immune
related diseases.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mesenchymal stromal cells (MSCs) have been shown to have
therapeutic potential for regenerative and anti-inﬂammatory
therapy [1–4]. Recent study had demonstrated that bone marrow-
derived MSCs (BM-MSCs) could suppress T-cell proliferation both
in phytohemagglutinin (PHA) induced T-cell proliferation and mix
lymphocyte models [5]. Although the immunomodulatory prop-
erty of MSCs has been demonstrated by many experiments, the
speciﬁc mechanisms are still controversial. Currently, several so-
luble factors either produced constitutively by MSCs or as a result
of cross-talk with target immune cells have been attributed to
immunomodulatory property of MSCs, including indoleamine 2,3-
dioxygenase (IDO) [6], prostaglandin E2 (PGE2) [7], interleukin 10
(IL-10) [8], nitric oxide (NO) [9], and hepatocyte growth factor
(HGF) [10]. Interestingly, interferon γ (IFN-γ), proinﬂammatory
cytokines secreted by activated T-cells, has been demonstrated to
stimulate IDO, PGE2, NO and HGF expressions [6].B.V. This is an open access article u
y, Department of Preclinical
athumthani 12120, Thailand.
tr).MSCs were ﬁrst recognized in bone marrow by Friedenstein
et al. since 1976 [11]. Until now, the studies of MSCs both in pre-
clinical and clinical studies have mainly focused on BM-MSCs.
However, the procedure of bone marrow aspiration is invasive and
the quality and quantity of BM-MSCs decreased with increasing
age of donors [12]. These problems limit the clinical use of BM-
MSCs. Currently; MSCs are isolated from various tissues, such as
adipose tissue, gingiva, amnion, placenta and umbilical cord.
Among these, amnion is one of the good candidate source of MSCs
that exhibit a high degree of self-renewal capacity and multi-dif-
ferentiation potential [13]. MSCs from amnion (AM-MSCs) have an
abundant of collection source than that of BM-MSCs and can be
collected with less ethical constraints.
Although the immunomodulatory property of BM-MSCs has
been extensively characterized [14,15], the immunosuppressive
behavior of AM-MSCs has not been studied. As BM-MSCs is the
most well characterized source of the MSCs, this study aim to
characterize and compare AM-MSCs in term of morphology, im-
munophenotype, differentiation potential, and immunosuppressive
capacity to those of BM-MSCs. In addition, the mechanism under-
lying immunosuppressive effect of AM-MSCs is studied and com-
pare to that of BM-MSCs. The results obtained from this study will
help to illuminate the biological properties of AM-MSCs and thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cations, including the treatment of immune related diseases.2. Methods
2.1. Cell isolation
This study was approved by the Human Ethics Committee of
Thammasat University No. I. All subjects participated in the study
after giving written informed consents. Bone marrow (n¼5) ob-
tained from healthy volunteer was carefully layered over Ficoll-
Hypaque solution (GE Healthcare, Sweden) and centrifuged at
100xg (Hettich, Universal 320 K, USA) for 30 min at 20 °C. The
amnion (n¼5) obtained from pregnant woman after normal de-
livery was minced into small pieces and digested with 1.6 mg/ml
collagenase XI (Sigma-Aldrich, USA) and 200 mg/ml deoxyr-
ibonuclease I (Sigma-Aldrich, USA). The cells from bone marrow
and amnion were collected and cultured in complete medium
[Dulbecco's Modiﬁed Eagle's Medium (GibcoBRL, USA.) containing
10% fetal bovine serum (FBS; BioWhittaker, USA), 2 mM
L-glutamine (GibcoBRL, USA), 100 U/ml penicillin and 100 mg/ml
streptomycin] at density of 1105 cells/cm2. After 72 h, non-
adherent cells were removed and fresh medium was added. The
culture medium was changed every 3–4 days. The cells were sub-
cultured using 0.25% trypsin-EDTA (GibcoBRL, USA.) and replated
at density of 1104 cells/cm2.
2.2. Immunophenotypical characterization
Primary culture from amnion and bone marrow (4105 cells)
were resuspended in 50 ml of phosphate buffer saline (PBS) and
incubated with 10 ml of ﬂuorescein isothiocyanate (FITC) or phy-
coerythrin (PE)-conjugated antibodies against CD34 (BD
Bioscience, USA), CD45 (BD Bioscience, USA.), CD73 (BD Bioscience,
USA.), CD90 (AbD Serotec, USA) or CD105 (AbD Serotec, USA.) for
30 min at 4 °C in the dark. After washing, the cells were ﬁxed with
1% paraformaldehyde. The positive cells were then identiﬁed by
comparison with isotype-match controls [FITC-conjugated mouse
immunoglobulin G1 (IgG1) and PE-conjugated mouse im-
munoglobulin G2a (IgG2a)]. At least ten thousand labeled cells
were acquired and analyzed using ﬂow cytometry (FACScalibur™,




2.3. Differentiation capacity assay
The adipogenic and osteogenic differentiation potential of cul-
tured MSCs were studied according to manufacturer's protocol. For
adipogenic differentiation, 3104 MSCs from each source were
cultured in adipogenic differentiation medium (Hyclone
s
Advance
STEM™, USA) with complete change of medium every 3 days. After
3 weeks, cells were stained with Oil Red-O (Sigma-Aldrich, USA) and
examined under inverted microscope. For osteogenic differentiation,
3104 MSCs were cultured in osteogenic differentiation medium
(Hyclone
s
AdvanceSTEM™, USA). The medium was replaced twice aTable 1





GAPDH 5′-GTCAACGGATTTGGTCGTATTG-3′week. After 21 days, cells were stained for alkaline phosphatase (ALP)
activity and observed under inverted microscope. Cells maintained in
completed medium served as controls.
2.4. Mixed lymphocyte reaction assay
Peripheral blood mononuclear cells (PB-MNCs) were prepared
from 10 ml of heparinized blood of healthy volunteer using Ficoll-
Hypaque solution. The stimulating PB-MNCs were treated with
10 mg/ml mitomycin C (Sigma-Aldrich, USA) for 2 h at 37 °C.
Thereafter, responding PB-MNCs (2.5104 cells) together with
stimulating PB-MNCs (7.5104 cells) were co-cultured in lym-
phocyte-cultured medium (RPMI 1640 medium supplemented
with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin) in the presence or absence of MSCs (2104
cells). PB-MNCs stimulated with 5 mg/ml phytohemagglutinin
(PHA; Sigma-Aldrich, USA) were used as a positive control. The
culture of PB-MNCs with MSCs was used as negative control. After
4 days, 100 ml of cell suspension from each well was transferred to
the new 96-well plates and 10 ml of Cell Counting Kit-8 (Dojindo
Laboratories, Japan) was added. After incubating at 37 °C for 4 h,
the absorbance at 450 nm was measured with a microplate reader
(BioTex, USA). The proliferative index was calculated according to
the manufacturer's instruction:
Proliferative index¼(O.D. sampleO.D. blank) / (O.D.control
O.D. blank)
To evaluation the effect of the number of MSCs on T-cell pro-
liferation, PHA activated PB-MNCs (2104 cells) were co-cultured
with MSCs at various ratios, 20:1, 10:1, 5:1, 2:1, 1:1, 2:1, for 4 days.
The culture of PHA activated PB-MNCs were used as controls. Cell
proliferation was examined using Cell Counting Kit-8 and pro-
liferative index was calculated as the above mention.
2.5. Gene expression analysis
MSCs (1105 cells) were stimulated with PHA activated PB-
MNCs (1105 cells) or 10 ng/ml IFN-γ (Peprotech, USA). MSCs co-
cultured with PB-MNCs (1105 cells) were used as controls. After
72 h, total RNA was extracted from the cultured MSCs using
PureLink™ RNA Mini Kit (Invitrogen, USA) and messenger RNA
was reverse transcribed to cDNA using SuperScript
s
III First Strand
Synthesis Kit (Invitrogen, USA). Quantitative real-time PCR sam-
ples were prepared using a SYBR
s
Green PCR Master Mix (Applied
Biosystems, USA). Primer sequences of indoleamine 2,3-dioxy-
genase (IDO), cyclooxygenase 2 (COX-2) and inducible nitric oxide
synthase (iNOS) were shown in Table 1. The ampliﬁcation was
performed on a Step one plus™ Real-Time PCR system (Applied
Biosystems, USA) using 40 cycles of ampliﬁcation (denaturation at
95 °C for 10 s, annealing at 60 °C for 10 s and extension at 72 °C for
20 s). Melting curves were assessed to ensure single products were
quantiﬁed. The quantitation was based on normalizing the gene of
interest to the invariant control gene (glyceraldehyde 3-phosphate
dehydrogenase; GAPDH). The data were analyzed by comparative
ΔΔCT method using StepOne™ Software version 2.2 and pre-
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MSCs (1106 cells) were stimulated with PHA activated PB-
MNCs (1106 cells) or 10 ng/ml IFN-γ (Peprotech, USA). MSCs co-
cultured with PB-MNCs (1106 cells) were used as controls.
After 72 h, the cells were resuspended in 200 ml of radio-
immunoprecipitation assay (RIPA) buffer (Cell Signaling Technol-
ogy, USA) contained 1 mM phenylmethylsulfonyl ﬂuoride (PMSF;
Sigma-Aldrich, USA). The protein concentrations were determined
using Bradford protein assay (Bio-Rad, USA).
The protein was separated on 10% sodium dodecyl sulfate (SDS)Fig. 1. The characteristic of cultured MSCs. (A) BM-MSCs at day 7. (B) Oil red-O staining o
(E) Oil red-O staining of AM-MSCs at day 28. (F) ALP staining of AM-MSCs at day 28
representative of the three different experiments.polyacrylamide gel at 100 V for 90 min. Subsequently, the proteins
were transferred to nitrocellulose membrane (Amersham Pharmacia,
USA) by electroblotter at 100 V for 90 min. Then, the membranes
were incubated with 5% nonfat dry milk for 1 h, followed with anti-
IDO antibody (Sigma-Aldrich, USA.) at a dilution of 1:250 overnight
at 4 °C. After washing, the membranes were then incubated with a
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Sig-
ma-Aldrich, USA) at a dilution of 1:2000 for 45 min at room tem-
perature. The signals were visualized using chromogenic substrate
detection system. After normalizing with actin, the densitometric
value was expressed as the mean7standard error of mean (SEM)f BM-MSCs at day 21. (C) ALP staining of BM-MSCs at day 14. (D) AM-MSCs at day 10.
. (G) Flow cytometric analysis of surface marker expression. The data shown are
Fig. 2. Mean value of proliferative index of responder T cells co-cultured with
stimulator T cells or PHA activated T cells in the presence or absence of MSCs. #,
*po0.05 signiﬁcantly different compared to MNCþstimulator and MNCþPHA,
respectively.
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2.7. Cytokine inhibition assays
To evaluate the involvement of IDO, COX-2 and iNOS in the
suppressive effect of MSCs, PHA activated PB-MNCs (2104 cells)
were co-cultured with MSCs (2104 cells) in the presented or
absented of chemical antagonists for IDO [1-Methyl-L-Tryptophan
(1-MT), 500 μM; Sigma-Aldrich, USA], COX-2 (Indomethacin,
20 μM; Sigma-Aldrich, USA), and iNOS [N-nitro-L-arginine methyl
ester (L-NAME), 1 mM; Sigma-Aldrich, USA]. The culture of PHA-
activated MNCs was used as the controls. After 4 days, cell pro-
liferation was examined using Cell Counting Kit-8 and proliferative
index was calculated as mention in the above section.
2.8. Statistical analysis
Data are presented as mean7standard error of mean. The
ANOVA test was used to assess the signiﬁcance of differences be-
tween observed data. p-values of less than 0.05 was considered to
be statistically signiﬁcant.3. Results
3.1. Morphology of MSCs
After plating, BM-MNCs exhibited a spherical shape and ﬂoatedin the media. After 24 h, some cells attached on plastic surface of
tissue culture ﬂask and exhibited elongated shape. On day 7, the
morphologically homogeneous population of spindle-shape cells
was observed (Fig. 1A). These cells could multiply rapidly and
reached 80% conﬂuence within 10 days. AM-MSCs exhibited a
spherical shape and ﬂoated in the media after initial plating. Some
cells exhibited elongated shape after 48 h. On day 10, the homo-
geneous populations of elongated, spindle-shape cells were ob-
served (Fig. 1D). After further cultured, these cells rapidly pro-
liferated and reached 80% conﬂuence within 14 days.
3.2. Immunophenotype of MSCs
AM-MSCs expressed high levels of typical MSCs markers; CD
73, CD90 and CD105, but did not express hematopoietic markers;
CD34 and CD45, similar to that of BM-MSCs. However, the per-
centages of cells which expressed those markers were slightly
difference from each MSC sources (Fig. 1G).
3.3. Differentiation potential of MSCs
After 3 weeks of adipogenic induction, AM-MSCs changed their
morphology from spindle shaped cell to become large cells and
shown accumulation of lipid vacuoles in their cytoplasm. These
lipid droplets were positive for oil-red-O staining similar to that of
differentiating BM-MSCs (Fig. 1B and E). For osteogenic induction,
AM-MSCs formed large nodules and had appearance of refringent
crystals in the cells after 3 weeks. Most of the cells were positive
for alkaline phosphatase staining similar to that of BM-MSCs
(Fig. 1C and F). The controls which cultured in complete DMEM
medium without any differentiation stimuli maintained the
ﬁbroblast like morphology and did not positive for oil-red-O or
alkaline phosphatase staining even after 3 weeks of culture.
3.4. Immunosuppressive effect of MSCs
The immunosuppressive effect of AM-MSCs and BM-MSCs
were examined using mixed lymphocyte model. In allogeneic sti-
mulation, the proliferative index was increased to 5.4470.63 in
comparison with the control. Interestingly, the proliferative index
of responder which was activated with PHA was increased to
11.1470.54 in comparison with control. After adding AM-MSCs,
the proliferative indices of both allogeneic stimulation and PHA
activated responder was signiﬁcantly decreased (po0.05) similar
to those of BM-MSCs (Fig. 2A).
The PHA-activated T cells co-cultured with MSCs at various
ratios demonstrated that AM-MSCs and BM-MSCs could suppress
T cell proliferation in dose dependent manner (Fig. 2B and C).
3.5. The expression of IDO, COX-2 and iNOS
To determine the expressions of cytokines involved in im-
munosuppression, MSCs were co-cultured with PHA-activated T
cells and the expressions of IDO, COX-2 and iNOS were examined
using quantitative real time PCR. The results showed that the ex-
pression of IDO was signiﬁcantly increased in both BM-MSCs and
AM-MSCs in comparison with the control (po0.05, Fig. 3A). In
addition, the expression of COX-2 and iNOS was signiﬁcantly in-
creased, especially in BM-MSCs, after co-cultured with PHA acti-
vated T cells in comparison to control (po0.05, Fig. 3B and C).
To determine the factor secreted from activated T cells that
could induce cytokine expression fromMSCs, the experiment were
performed by adding IFN-γ into the culture of MSCs and the
expressions of IDO, COX-2 and iNOS were examined using quan-
titative real time PCR. The result demonstrated that the level of
IDO expression was signiﬁcantly increased in both AM-MSCs and
Fig. 3. (A–C) Relative gene expression in MSCs after cultured with PHA activated T cells or IFN-γ. (D, E) Western blot analysis of IDO expression in MSCs after cultured with
PHA activated T cells or IFN-γ. *,#po0.05 signiﬁcantly different compared to BM-MSCsþMNC and AM-MSCþMNC, respectively.
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terestingly, the expression of IDO in MSCs stimulated with IFN-γ
was signiﬁcantly higher than those of MSCs co-cultured with PHA-
activated T cells. However, both AM-MSCs and BM-MSCs stimu-
lated with IFN-γ did not express COX-2. Interestingly, AM-MSCs
stimulated with IFN-γ could express iNOS but in lower level than
that of MSCs co-cultured with PHA-activated T cells (Fig. 3B and C).
Moreover, the expression of protein, IDO, was signiﬁcantly in-
creased in both AM-MSCs and BM-MSCs after co-cultured with
PHA-activated T cells or stimulated with IFN-γ in comparison with
the control. Fascinatingly, the expression IDO in MSCs stimulated
with IFN-γ was signiﬁcantly higher than those of MSCs co-cul-
tured with PHA-activated T cells. (po0.05, Fig. 3D and E).
3.6. Immunosuppressive effect of MSCs after cytokine inhibition
To determine the role of soluble factors, IDO, COX-2 and iNOS,
in MSCs mediated T cell suppression; the inhibition assay was
performed using chemical antagonists to those cytokines. The re-
sult demonstrated that the proliferation of PHA-activated T cells
could reverse to the level of positive control (PB-MNCsþPHA)
after co-cultured with BM-MSCs in the presence of 1-MT. The
proliferative index of PHA-activated T cells co-cultured with AM-
MSCs in the presented of 1-MT were higher than that of PHA-ac-
tivated T cells co-cultured with AM-MSCs without 1-MT (po0.05,
Fig. 4A). Interestingly, the proliferative index of these PHA-acti-
vated T cells did not reverse to the level of control (PB-
MNCsþPHA). Indomethacin and L-NAME could also signiﬁcantly
reverse the proliferation of PHA-activated T cells which were co-
cultured with BM-MSCs and AM-MSCs (po0.05, Fig. 4B and C),
however, the proliferative index of these PHA-activated T cells did
not reverse to the level of control.Fig. 4. Mean value of proliferative index of PHA activated T cells co-cultured with MSCs
in the presence or absence of 1-MT (A), Indomethacin (B), and L-NAME (C). *, #, $po0.05
signiﬁcantly different compared to MNCþPHAþBM-MSCs, MNCþPHAþAM-MSC and
MNCþPHAþBM-MSCsþ1MT, respectively.4. Discussion
Human MSCs, mostly BM-MSCs, endow a great promise for
application in regenerative medicine and immune related diseases
[16]. However, the use of BM-MSCs has some limitations [12].
Therefore, the search for alternative sources of MSCs for ther-
apeutic application is important. In this regard, the amnion re-
presents an abundant source of MSCs that could be exploited fortherapeutic application. In this study, AM-MSCs exhibited the
unique stem cell-like properties similar to BM-MSCs including 1)
in vitro proliferation as plastic-adherent cells with ﬁbroblast-like
morphology, 2) the expression of MSC immunophenotype, 3) the
capacity to differentiate toward osteogenic and adipogenic linea-
ges. The presented data demonstrate that AM-MSCs share the
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Society for Cellular Therapy [17].
Although MSCs from difference sources could share many si-
milarities, however, some studies reported the differences at
transcriptional and proteomic levels which possess different bio-
logical and functional characteristics [18,19]. Therefore, it is pos-
sible that differences in the regulation of immunosuppression may
exist. Recent studies have shown that BM-MSCs can suppress the T
cell proliferation induced by alloantigens or mitogens through an
IDO dependent mechanism [20–22]. However, the im-
munosuppressive capacity of AM-MSCs and the speciﬁc mechan-
isms underlying AM-MSCs-mediated immunosuppression have
been poorly studied. This study demonstrated that AM-MSCs could
inhibit T-cell proliferation at the similar degree with BM-MSCs.
Moreover, the number of MSCs has an effect to the im-
munosuppressive capacity of both BM-MSCs and AM-MSCs. Both
of them could inhibit T cell proliferation in dose-dependent
manner.
Recent studies have shown that the inhibition of T cell pro-
liferation by BM-MSCs appeared to be mediated by both cell–cell
interaction [23] and release of soluble factors such as IFN-γ
[10,24]. The result from this study supports a crucial role of IFN-γ
in inducing an immunosuppressive mechanism [10]. The addition
of IFN-γ could signiﬁcantly activate IDO expression in BM-MSCs
and AM-MSCs. In addition, the protein expression exhibited a si-
milar proﬁled to gene expression. Interesting, the expression of
protein, IDO, in both AM-MSCs and BM-MSCs which stimulated
with IFN-γ showed signiﬁcantly higher than that of MSCs stimu-
lated with activated T cells. It might be possible that the expres-
sion of IDO from both BM-MSCs and AM-MSCs is induced by IFN-γ
released from activated T cells.
To determine whether protein, IDO, is exactly regulator for T
cell suppression, inhibition assay using 1-MT were performed. The
results demonstrated that the proliferative index of activated T
cells co-cultured with BM-MSCs was signiﬁcantly restored once
IDO was inhibited. Interestingly, AM-MSCs exhibited a less re-
sponse to 1-MT compared to BM-MSCs. Blocking IDO using 1-MT
could not completely block immunosuppressive function of AM-
MSCs. It might be possible that IDO partly contributed to im-
munosuppressive function of AM-MSCs which is different from
BM-MSCs which use IDO as the main pathway for T cell suppres-
sion [25]. In addition to IDO, several cytokines and soluble mole-
cules with immunomodulatory capacity, including PGE2 and NO,
have been implicated in the mechanism of immunosuppression by
MSCs [9,26]. To determine whether PGE2 produced by MSCs could
account for the inhibition of T cell proliferation, the effect of
blocking cyclooxygenase 2 (COX-2) was examined using in-
domethacin that blocks prostaglandin biosynthesis by inhibiting
COX-2 [27]. The result showed that T-cell proliferation was sig-
niﬁcantly restored once PGE2 production was prevented. Similar to
PGE2, blocking NO synthesis interfered with MSC-mediated im-
munosuppression. However, inhibition of these molecules does
not result in a complete loss of the immunosuppressive activity of
both AM-MSCs and BM-MSCs. Some discrepancies regarding the
requirement of PGE2 and NO on the mechanism of im-
munosuppression by MSCs exist [28,29]. However, overall results
suggested that, although involved, PGE2 and NO are not the main
and crucial immunosuppressive mechanism.
Our ﬁnding demonstrates that cells isolated from amnion
possess MSC characteristics. Remarkably, AM-MSCs displayed a
similar degree of immunosuppression to that of BM-MSCs. Al-
though immunosuppression of AM-MSCs rely on a highly complex
mechanism with many factors involved, the key mechanism in-
volved with the production of the tryptophan metabolizing en-
zyme, IDO, which is partly mediated by the stimulation of AM-
MSCs with IFN-γ.Acknowledgments
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